Table 1: matched patients, on prophylaxis over T1 & T2, weight information noted (n = 129/156)		Standard FVIII only over T2 N = 62 patients	Standard FVIII, then EHL FVIII over T2 N = 29 patients	rFVIII‐Fc only over T2 N = 38 patients	Total N = 129 patients
T1 July 2015 ‐ June 2016	Weight in kgs (mean ± sd)	51.4 ± 24.0	53.6 ± 26.8	57.1 ± 25.5	53.5 ± 25.0
	Prescribed FVIII (IU/patient/year) (mean ± sd)	207,529 ± 120,685	237,328 ± 127,163	230,400 ± 113,055	220,965 ± 119,781
	Prescribed FVIII (IU/kg/week/patient) (mean ± sd)	81.0 ± 30.5	88.2 ± 25.9	83.1 ± 38.7 a	83.2 ± 32.1 b
T2 July 2017–June 2018	Weight in kgs (mean ± sd)	55.1 ± 21.3	56.3 ± 25.4	61.5 ± 23.5	57.3 ± 22.9
	Prescribed FVIII (IU/patient/year) (mean ± SD)	211,135 ± 106,154	TOTAL: 232,208 ± 98,809 (52 w) =STD: 137,267 ± 81,772 (30 w) +EHL: 94,941 ± 61,534 (22 w)	220,402 ± 91,138	218,602 ± 99,884
	Prescribed FVIII (IU/kg/week/patient) (mean ± SD)	76.9 ± 28.3	TOTAL: 86.7 ± 29.3 (52 w) =STD: 86.4 ± 31.1 (30 w) and EHL: 86.6 ± 29.8 (22 w)	75.2 ± 38.0 a	78.6 ± 31.7 b

^a Wilcoxon signed‐rank test, significative, α = 5% (P = 0.048).

^b Wilcoxon signed‐rank test, significative, α = 5% (P = 0.006).